GlassScriptPhysician profile
Mark A Hulsey
NPI 1932142361
$775.53
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $215 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $244.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $124.63 | 2019 | |
| Lilly USA, LLC | $102.61 | 2021 | |
| Abbvie INC. | $90.84 | 2019-2020 | |
| Amgen INC. | $83.65 | 2019 | |
| Genentech USA, INC. | $64.50 | 2019-2020 | |
| Pfizer INC. | $18.90 | 2019 | |
| Celgene Corporation | $17.78 | 2019 | |
| Glaxosmithkline, LLC. | $15.23 | 2019 | |
| Horizon Therapeutics Plc | $12.73 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hulsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.